Polymarket has introduced a new market on its U.S. app that allows users to trade on Bitcoin's price direction over 15-minute intervals. This feature lets millions of users bet on whether Bitcoin will rise or fall within each short period, providing a fast-paced trading experience. The availability of this market on the U.S. app could attract more active traders interested in short-term cryptocurrency movements.
Polymarket's new U.S. app feature offers 15-minute Bitcoin price direction trading. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 28, 2026 22:32 WIB: out of 50 major cryptocurrencies, 10 rose and 39 fell today. Notable movers include ONE at Rp45 with a 12.81% increase and a typical hold time of 152 days, ALGO at Rp2,351 up 12.43%, and BAL at Rp16,297 rising 11.14%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
